Temozolomide

Catalog No.S1237 Synonyms: CCRG81045, NSC 362856

Temozolomide Chemical Structure

Molecular Weight(MW): 194.15

Temozolomide is a monofunctional SN-1 alkylating agent that can modify nitrogen atoms in the DNA ring and the extracyclic oxygen group, chemically converted to MTIC and degrades to methyldiazonium cation, which transfers methyl groups to DNA at physiologic pH. A DNA damage inducer in L-1210 and L-1210/BCNU cells.

Size Price Stock Quantity  
In DMSO USD 64 In stock
USD 70 In stock
USD 170 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 10 Publications

7 Customer Reviews

  • C57BL/6 mice were implanted in the striatum with citrine-GL26-Cherry-HMGB1, which were stably transfected to express the YFP citrine and HMGB1 fused to red fluorescent protein cherry. Fourteen days later, they were treated with saline, Ad-TK+Ad-Flt3L, or Ad-TK+Ad-Flt3L+TMZ (temozolomide). Five days after treatment, the cellular location of cherry-HMGB1 in these cells was assessed by confocal microscopy. Arrows, tumor cells (green) with cytoplasmic HMGB1 (red).

    Clin Cancer Res 2014 20(6), 1555-65. Temozolomide purchased from Selleck.

    D, Scramble (SCR), H82, H865, and H1836 cells were treated with AZD1775 (100 nmol/L) and temozolomide (1 μmol/L) for 24 hours; WEE1 KD cells were treated with just temozolomide (1 μmol/L) for 24 hours. The cells were lysed at 24 hours and subjected to Western blot analysis for phosphorylated WEE1 (pWEE1_S642), pCDC2_Y15 (WEE1 downstream effector), γH2AX (DNA damage marker), PH3 (mitotic marker), cleaved caspase-3 (apoptotic marker), and actin (loading control). E, SCR and WEE1 KD H82, H865, and H1836 cells were treated as described in D and subjected to Western blot analysis for DNA repair markers pATM_S1981, MRE11, RAD51, and E2F1. Actin was used as a loading control.

    Clin Cancer Res, 2017, 23(20):6239-6253. Temozolomide purchased from Selleck.

  • Talazoparib and temozolomide exhibit marked combinatorial efficacy in PDXs. A, Western blot against MGMT by near-infrared imaging in PDX models.

    Clin Cancer Res, 2017, 23(2):523-535. Temozolomide purchased from Selleck.

    J Control Release, 2018, 269:245-257. Temozolomide purchased from Selleck.

  • Viability of U87 cells(A) assessed by the Alamar blue assay, 72 h after transfection with siRNA anti-survivin (siSURV) or with siMUT and/or cell incubation with the chemotherapeutical drugs temozolomide (TMZ) and Bliss interaction index (B) determined for the combined effects on cell viability of survivin silencing plus treatment with each drug. Cells were transfected, for 4 h, with (14Ser)2N5/siRNA/HL complexes and, after an additional period of 20 h, cells were incubated with 400 μM TMZ(A) for 48 h. Results, representative of at least three independent experiments, are expressed as a percentage of the nontreated control cells. Combined treatment (dotted bar) was compared with the single drug treatment (gray bar) (**p < 0.01, ***p < 0.001) and the Bliss interaction index of each combined treatment was compared with the theoretical value expected for an additive effect (1.0) (#p < 0.05, ns, non-significant).

    Eur J Pharm Biopharm, 2016, 104:7-18.. Temozolomide purchased from Selleck.

    Cells were plated and 12 h after plating were treated with MMF (5 µM), FTY720 (50 nM), Temozolomide (TMZ, 3 µM) or in combination as indicated for 12 h. Cell viability was assessed by live / dead assay.

    Cancer Biol Ther, 2014, 15(12):1646-57. Temozolomide purchased from Selleck.

  • Establishment of TMZ-resistant (TR) GBM cell lines. a-d, Evaluation of temozolomide resistance in four glioblastoma cell lines. Cells were cultured in the presence of 5-600 μM of TMZ. A dose-dependent association between the survival rate of cells and TMZ concentration can be observed. Each group was cultured for 24 h in the presence of different concentrations of TMZ, followed by an evaluation of IC50 for TMZ inhibited growth in A172-TR/A172, U118-TR/U118, U251-TR/U251 and U87-TR/U87

    Neurochem Res, 2016, 41(12):3192-3205. Temozolomide purchased from Selleck.

Purity & Quality Control

Choose Selective DNA/RNA Synthesis Inhibitors

Biological Activity

Description Temozolomide is a monofunctional SN-1 alkylating agent that can modify nitrogen atoms in the DNA ring and the extracyclic oxygen group, chemically converted to MTIC and degrades to methyldiazonium cation, which transfers methyl groups to DNA at physiologic pH. A DNA damage inducer in L-1210 and L-1210/BCNU cells.
Features Methazolastone is a second-generation alkylating agent.
Targets
DNA replication [1]
(L-1210, L-1210/BCNU cells)
In vitro

Methazolastone causes formation of DNA alkali-labile sites which are present in similar amounts and repaired at a similar rate in L-1210 and L-1210/BCNU cell lines. In L-1210 but not in L-1210/BCNU methazolastone induces an arrest of cells in SL-G2-M phases.[1] Methazolastone sensitivity of both chemo-sensitive and resistant cells (D54-R and U87-R) is enhanced significantly under hyperoxia. Both Methazolastone and hyperoxia are associated with increased phosphorylation of ERK p44/42 MAPK (Erk1/2), but to a lesser extent in D54-R cells, suggesting that Erk1/2 activity may be involved in regulation of hyperoxia and Methazolastone-mediated cell death. Hyperoxia enhances Methazolastone toxicity in GBM cells by induction of apoptosis, possibly via MAPK-related pathways. [2] Methazolastone induces in monocytes the DNA damage response pathways ATM-Chk2 and ATR-Chk1 resulting in p53 activation. [3] Chronic Methazolastone exposure results in acquired Methazolastone-resistance and elevates miR-21 expression. [4] Methazolastone treatment triggers endoplasmic reticula (ER) stress with increased expression of GADD153 and GRP78 proteins, and deceases pro-caspase 12 protein. Methazolastone induces autophagy through mitochondrial damage- and ER stress-dependent mechanisms to protect glioma cells. [5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Kelly NY\P[|VmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYfsV4hCPDhiaB?= NGXhO|JKSzVyPUGzPU4zOOLCidMx5qCKPS57NTFOwG0> MUmyOVk3ODJ6Mh?=
KellyCis83 MnLiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn\6OFghcA>? MkjNTWM2OD1{NUGuNFDjiIoEsfMAjVE2Njd3IN88US=> Mm\jNlU6PjB{OEK=
SK-N-AS M4fwdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIDtfIs1QCCq NHS5[XFKSzVyPUKyO{44OOLCidMx5qCKOjJwMUWg{txO Mmi1NlU6PjB{OEK=
SK-N-ASCis24 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUi0PEBp Mo\DTWM2OD12OECuOlDjiIoEsfMAjVExOS5zNTFOwG0> MnHENlU6PjB{OEK=
CHP-212 Ml\4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYW0PEBp NIjidnhKSzVyPUeuPVfjiIoEsfMAjVAvPjlizszN NGm3[lkzPTl4MEK4Ni=>
CHP-212Cis100 NU\x[GdNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MorOOFghcA>? NFzGemtKSzVyPUmuOVXjiIoEsfMAjVAvQDhizszN M1XieFI2QTZyMkiy
U87  NH36e|lHfW6ldHnvckBCe3OjeR?= M2fFe|ExOCEQvF2= MUeyOE04OiCq M2W4WYlv\HWlZYOgSINTOSCneIDy[ZN{cW:w MXKyOVgxQDh4OB?=
LN229 MmHuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX:wMVUxKM7:TR?= NF7yWVZKSzVyPUG2JO69VQ>? NFzmdI8zPTd3MEK3Ny=>
TR-LN229 NUHFcHBJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF;VSZUxNTVyIN88US=> MmHqTWM2OD15NzFOwG0> M{j3eVI2PzVyMkez
U87  MojFRZBweHSxc3nzJGF{e2G7 MmDXNQKBmzJyMPMAjeK2VQ>? NXnrdWc6OjRiaB?= MoPQ[Y5p[W6lZYOgR3EhcW6mdXPl[EBieG:ydH;zbZM> MmL2NlU3QDF4Nki=
U251MG NULmblg4SXCxcITvd4l{KEG|c3H5 M37sOlExOMLizszN Mkj1OFghcA>? NXHheW1YWEKV NGrvb3VqdmS3Y3XzJIFxd3C2b4Ppdy=> NYTjcJlyOjV4OEC0OlQ>
U87MG Mm\uRZBweHSxc3nzJGF{e2G7 MX6xNFDDqM7:TR?= MXe0PEBp MknOVGJU MYXpcoR2[2W|IHHwc5B1d3Orcx?= NXjpVFVrOjV4OEC0OlQ>
U87 NWjtSWI6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkXROVAuOzVyIN88US=> NIfXTZI1QMLiaNMg MX3pcohq[mm2czDj[YxtKGe{b4f0bEB{dGmpaITsfS=> Mnm2NlU2PTR{MkO=
U118  M1zUPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{XtPFUxNTN3MDFOwG0> NW\YeG97PDkEoHlCpC=> M1XSZ4lvcGmkaYTzJINmdGxiZ4Lve5RpKHOuaXfoeIx6 NG\GOGMzPTV3NEKyNy=>
U87 NHPOTZlHfW6ldHnvckBCe3OjeR?= MoTFNlUxNzN3MDFOwG0> NHrXbGg1QMLiaNMg NGjWS2JmdmijbnPld{BVVVhvaX7keYNm\CCyLWDLR{1x[W5iZHXjdoVie2V? M13Ee|I2PTV2MkKz
U118  NH7lRW5HfW6ldHnvckBCe3OjeR?= M1y4VFI2OC9|NUCg{txO NEjDOlE1QMLiaNMg MnjK[Y5p[W6lZYOgWG1ZNWmwZIXj[YQheC2SS1OtdIFvKGSnY4LlZZNm MWqyOVU2PDJ{Mx?=
U87 M360PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnjGNlUxNzN3MDFOwG0> NXeyfHNnPDkEoHlCpC=> M2\Uc4lv[3KnYYPld{B1cGVicHXyZ4VvfGGpZTDv[kBk\WyuczDpckBUKGGwZDDHNk9OyqClb4Ty[YF1\WRid3n0bEBVVVh? NVXGPWZ7OjV3NUSyNlM>
A375 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkPWOFjDqGkEoB?= M2[3c2lEPTB;Mk[1JO69VQ>? M4T1XlI2PTJ2NUWy
A2058 NGDmXZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXHJeJFZPDkEoHlCpC=> M{i0SGlEPTB;MUKg{txO MYmyOVUzPDV3Mh?=
M238 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWm0POKhcMLi NGHjdY1KSzVyPUSwJO69VQ>? MnX5NlU2OjR3NUK=
M249 M2XUPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFPm[WQ1QMLiaNMg NXX0NHEzUUN3ME2yOVQh|ryP MWSyOVUzPDV3Mh?=
M21 NGflbppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH;n[IE1QMLiaNMg NX;ucmVVUUN3ME2yNlEh|ryP MWSyOVUzPDV3Mh?=
U251 MYXDfZRwfG:6aYT5JGF{e2G7 NXnBb5dCOjBizszNxsA> Mmr2OFjDqGkEoB?= Mm\UdoVlfWOnZIOgeIhmKHCncnPlcpRi\2W|IH;mJINwdG:waXXzJIZwem2nZB?= Mo\tNlU1OzR|OEG=
LN229 M2nvRWN6fG:2b4jpeJkhSXO|YYm= NHzZcGszOCEQvF5CpC=> MlfSOFjDqGkEoB?= MXny[YR2[2WmczD0bIUheGW{Y3XueIFo\XNib3[gZ49td26rZYOg[o9zdWWm M{DyTFI2PDN2M{ix
U373MG-LUC MlXNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV:3NkBp NXXFS2RmUUN3ME62NFAh|ryP M4PGflI2PDNzOUWz
U87  MlvoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUHWSnFHOjVvMkCwJO69VQ>? NHHseHE1QMLiaNMg MVTpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> M{HWdVI2PDByN{S1
U251 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3mwPFI2NTJyMDFOwG0> NXnwNoZQPDkEoHlCpC=> MVPpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> M{KzNVI2PDByN{S1
U251 NXrOToRFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnX2NVAxNTRyMDFOwG0> MnLGO|IwQTZiaB?= Mne4eIhmKGGwdHmtdJJwdGmoZYLheIl3\SCnZn\lZ5Qh[2GwIHLlJIVvcGGwY3XkJIJ6KGexc4P5dI9tKGWwaHHuZ4VlKMLi NHjVfJkzPTN5NUK3NS=>
U373 NFzid3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHLRfZEyODBvNECwJO69VQ>? MnTrO|IwQTZiaB?= NUW4dYVRfGinIHHueIkueHKxbHnm[ZJifGm4ZTDl[oZm[3RiY3HuJIJmKGWwaHHuZ4VlKGK7IHfvd5N6eG:uIHXubIFv[2WmINMg MVqyOVM4PTJ5MR?=
U343 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYe2PXFCOTByLUSwNEDPxE1? NXT0N3FJPzJxOU[gbC=> MmfWeIhmKGGwdHmtdJJwdGmoZYLheIl3\SCnZn\lZ5Qh[2GwIHLlJIVvcGGwY3XkJIJ6KGexc4P5dI9tKGWwaHHuZ4VlKMLi MnrKNlU{PzV{N{G=
U87MG-luc2 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVPRZ4NnOTByLUSwNEDPxE1? NUS0UZV3PzJxOU[gbC=> MnnHeIhmKGGwdHmtdJJwdGmoZYLheIl3\SCnZn\lZ5Qh[2GwIHLlJIVvcGGwY3XkJIJ6KGexc4P5dI9tKGWwaHHuZ4VlKMLi MkTiNlU{PzV{N{G=
U87 MXnGeY5kfGmxbjDBd5NigQ>? M4PrWlIxOCEQvF2= NX7sRmVkPDhiaB?= NVH2[Ys{cW6lcnXhd4V{KEKUQ1OzJI1TVkFiZYjwdoV{e2mxbh?= NF7IcnozPTN|N{eyNS=>
U251 NUC5[ZlwTnWwY4Tpc44hSXO|YYm= M{PwWFIxOCEQvF2= MlHjOFghcA>? M3Trbolv[3KnYYPld{BDWkOFMzDtVm5CKGW6cILld5Nqd25? M3q1R|I2OzN5N{Kx
A172 MXHGeY5kfGmxbjDBd5NigQ>? NI\IOVkzODBizszN M4fWW|Q5KGh? NFuxdHdqdmO{ZXHz[ZMhSlKFQ{OgcXJPSSCneIDy[ZN{cW:w M4HQO|I2OzN5N{Kx
U251 M4L2WGZ2dmO2aX;uJGF{e2G7 M2TxNVIxOCEQvF2= NXP3W|hJPDhiaB?= NYTiZ5NlcW6lcnXhd4V{KHSqZTDlfJBz\XO|aX;uJI9nKEKUQ1GxMEBDWkODMjygVmFFPTFiYX7kJGZCVkOGMh?= MnHTNlU{Ozd5MkG=
A172 M1GzOGZ2dmO2aX;uJGF{e2G7 NG\FRZozODBizszN MmqxOFghcA>? NFvPN3ZqdmO{ZXHz[ZMhfGinIHX4dJJme3Orb36gc4YhSlKFQUGsJGJTS0F{LDDSRWQ2OSCjbnSgSmFPS0R{ M2riRlI2OzN5N{Kx
U87 NVrESWRFTnWwY4Tpc44hSXO|YYm= M3fWe|IxOCEQvF2= MWKyOE84Oi9zMkCgbC=> MXvpcoNz\WG|ZYOg{tNJOkG[IH\vZ4kh\m:{bXH0bY9vKHSrbXWt[IVx\W6mZX70cJk> M2HsVVI2OzN5N{Kx
U251 M2KwfmZ2dmO2aX;uJGF{e2G7 NHHRb|czODBizszN MVGyOE84Oi9zMkCgbC=> Mn3nbY5kemWjc3XzJO6{UDKDWDDmc4NqKG[xcn3heIlwdiC2aX3lMYRmeGWwZHXueIx6 NUn5cnduOjV|M{e3NlE>
A172 NFuzTlFHfW6ldHnvckBCe3OjeR?= M1i2[VIxOCEQvF2= MUSyOE84Oi9zMkCgbC=> M{\obIlv[3KnYYPld{DPu0h{QWig[o9kcSCob4LtZZRqd25idHnt[U1l\XCnbnTlcpRtgQ>? NU\HfYZuOjV|M{e3NlE>
SNB19V MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHHRUW44KGR? MlXzSG1UVw>? Mn7rS2k2OD1|NT63xtEyOiEQvF2= M3[yWlI2Ojd5NESx
SNB19M MkHrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUG3JIQ> MUjEUXNQ NUfTN5NpT0l3ME20OlkvQcLzOEig{txO MWiyOVI4PzR2MR?=
SNB19VR Ml\yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX:3JIQ> M3nBOWROW09? M335c2dKPTB;MkiwMlLDuTF6IN88US=> NF61ZmUzPTJ5N{S0NS=>
U373V NVvIcpF5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlTJO{Bl NIj3e4pFVVOR MnzpS2k2OD14OD6wxtE{OiEQvF2= NGCxc40zPTJ5N{S0NS=>
U373M NWf2WGhIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoT5O{Bl M4eze2ROW09? NIj4S2lIUTVyPUO2PE44yrF6NjFOwG0> MmfiNlUzPzd2NEG=
U373VR MkPCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUjr[3VkPyCm M3nPOWROW09? NXzmbnF1T0l3ME2yPFgvQMLzM{Og{txO NF3sUHUzPTJ5N{S0NS=>
U87MG NGjPWJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUK3JIQ> NGTOUppFVVOR NIjuPGNIUTVyPUO4MlPDuTJyIN88US=> NISzdXYzPTJ5N{S0NS=>
HCT116 NIHOUZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEWxRo44KGR? Mo\zSG1UVw>? NX;Qe4xCT0l3ME21O|kvQcLzM{Kg{txO MoXkNlUzPzd2NEG=
DLD1 NV7QbJJWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV:3JIQ> MlXSSG1UVw>? NGS1cVJIUTVyPUWwNU41yrF7MzFOwG0> NInEbFEzPTJ5N{S0NS=>
MRC5 NWfWdlBUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXi2b5J3PyCm NEDidoVFVVOR NUnZNFZPT0l3ME20OFkvPMLzODFOwG0> Mly1NlUzPzd2NEG=
SNB19V  MlHMSpVv[3Srb36gRZN{[Xl? MYqxNFAh|ryPwrDUUXo> MlTUNE04OiCq NHn3ToxqdmO{ZXHz[ZMh|rOKMlHYJIV5eHKnc4Ppc44h[mW2d3XlckAyPiCjbnSgO|IhcA>? NWH3PZlIOjV{N{e0OFE>
T98G  M3i3bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF3JSZQ2NzFyL{G1JO69VQ>? Mli1NlTDqGh? MoTGbY5lfWOnczDj[YxtKGSnYYToJIRwe2VvZHXw[Y5l\W62bImgZYZ1\XJiY3;uZ49ucXSjboSteIVud3qxbH;tbYRmKHerdHigUnBmPi2SRGS= NWLq[3NIOjV{NkK5OlE>
U251  NXTnPVkxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnHpOU8yOC9zNTFOwG0> M4nKOVI1yqCq NHXhXJZqdmS3Y3XzJINmdGxiZHXheIgh\G:|ZT3k[ZBmdmSnboTsfUBi\nSncjDjc45kd22rdHHueE11\W2xen;sc41q\GVid3n0bEBPWGV4LWDEWC=> M4G1cFI2OjZ{OU[x
T98G  NWjHS5NETnWwY4Tpc44hSXO|YYm= MlrMNVUh|ryP NF7CRpEzPMLiaB?= Mm[4bY5kemWjc3XzJGRPSS2ocnHncYVvfGG2aX;uJIlvKE6SZU[tVGRVKHS{ZXH0[YQh\2yrb33hJINmdGy| NFf0VVczPTJ4Mkm2NS=>
U251  NEXwOnZHfW6ldHnvckBCe3OjeR?= NVvKXHZ[OTVizszN MYWyOOKhcA>? NISxcJVqdmO{ZXHz[ZMhTE6DLX\yZYdu\W62YYTpc44hcW5iTmDlOk1RTFRidILlZZRm\CCpbHnvcYEh[2WubIO= M4X5V|I2OjZ{OU[x
U-87 MG MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHvLTZI4OiCq MlPwTWM2OD1yLkmzJI1OyqB? MoHuNlUzPDV|M{K=
U-118 MG NFu0WW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIC4eoc4OiCq MoLUTWM2OD1zLkC1JI1OyqB? MmDWNlUzPDV|M{K=
U87 NYDTe4RMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH\PNpUzPCCq M3m1TWlEPTB;Mk[wMlM1KM7:TdMg MYeyOVE4OzJ|Mx?=
U87 GSLCs NYj4fItST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXW5NZA1OjRiaB?= NU\TZmN7UUN3ME23OlYvOTFizszNxsA> MonnNlUyPzN{M{O=
U87MG NXrxZ29CT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXu3NkBp NHnqT|hKSzVyPUG1MlYzPSEQvF5CpC=> NX;NSW84OjVyNUC5NVU>
U251 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUKxNFAuPDByIN88US=> Ml\ROFghcA>? M{m1WGROW09? M1K3WolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NWXPOXFzOjR4MkO3N|Y>
U87 M{\EZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF60WpUyODBvNECwJO69VQ>? Mkj6OFghcA>? NHrzNFBFVVOR M2K5bIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NH;PZ2szPDZ{M{ezOi=>
MDA-MB-231-br MmXvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF36U40xNTFyIN88US=> NGiwUos1QCCq MoTrSG1UVw>? M3nBPYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MkD1NlQ3OjN5M{[=
HCC-1937 MlzlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX2xU4tkOC1|MECg{txO MnjkOFghcA>? NHSwdWtFVVOR M{GxTIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MW[yOFYzOzd|Nh?=
MDA-MB-231 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXvadnNNOC12MDFOwG0> NF;C[YY1QCCq MWjEUXNQ M4e3UIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NX3FeoY6OjR4MkO3N|Y>
MDA-MB-468 MlrBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV2wMVUxOCEQvF2= NWTCU4hLPDhiaB?= MYXEUXNQ Mm\5bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> M3PIeVI1PjJ|N{O2
T47D MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXHD[2c2OC1zMECg{txO MlvxOFghcA>? MVnEUXNQ NEDXc2RqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NX;ySZhzOjR4MkO3N|Y>
MCF7 NVHuNWV6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NELYXWYxNTFyMECg{txO MmnUOFghcA>? MWnEUXNQ NHfXdZBqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? M1r1UFI1PjJ|N{O2
Hs683 MnLuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFPoZYoxNTFyMECg{txO MYC5OkBp M3uzXWlEPTB;MUK4Mlkh|ryP NXjGNGQzOjR2OUW5NFc>
U87 NFL3TINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHHIbVcxNTFyMECg{txO NGeybYQ6PiCq M1HXSGlEPTB;MUiuOFUh|ryP NYH1OG92OjR2OUW5NFc>
LNZ308 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWGwMVExODBizszN NIO3[IY6PiCq MUnJR|UxRTN{Nj63JO69VQ>? MoDhNlQ1QTV7MEe=
U87 NED5S5NCeG:ydH;zbZMhSXO|YYm= NXnwNmdZOTByIN88US=> MUW0PEBp NW\VepdDTE2VTx?= NHez[WFqdmO{ZXHz[ZMhfGinIHPhd5Bie2VvMz:3JIFkfGm4aYT5 M1nkUVI1PDhzNUi2
U251  MWXBdI9xfG:|aYOgRZN{[Xl? M1H6VlExOCEQvF2= M37YO|Q5KGh? NUfOTGZXTE2VTx?= NUjueGVmcW6lcnXhd4V{KHSqZTDjZZNx[XOnLUOvO{Bi[3Srdnn0fS=> MWiyOFQ5OTV6Nh?=
U251 NHzVb3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVSyOEBp NXrZV5pZUUN3ME24Ok4zQeLCidMx5qCKOS53ODFOwG0> MY[yOFMzPjl3NB?=
U251 NUfxbGlmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mki1OFghcA>? MkHoTWM2OD15NT6zOQKBkcLz4pEJNU4xOiEQvF2= NUXoRnAzOjR|Mk[5OVQ>
U251 NX\0fJNxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVHZT5hCPzJiaB?= MYLJR|UxRTd{LkSy5qCKyrIkgJmxMlQ2KM7:TR?= MXKyOFMzPjl3NB?=
U251 MnHLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXrNRnE2QTZiaB?= MXvJR|UxRTZ7Lkiy5qCKyrIkgJmzMlA1KM7:TR?= NG\3b2szPDN{Nkm1OC=>
T98G MnjDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn7JNE04PTBizszN MmrjO|IwQTZiaB?= M{[zWYlvcGmkaYTzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ MWSyOFMzPDB6MB?=
U251-MG NXX1bZU2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkHRNE05ODBizszN MknvO|IhcA>? M2PMdIlvcGmkaYTzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ MWeyOFA6OzZ|MB?=
D54-MG NWnRN5lFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVWxOmxEOC16MECg{txO MXK3NkBp NETqXndqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= NXHibodbOjRyOUO2N|A>
SHG-44 NH7kempIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWCxNE0zODBizszN Mlz3PVYhcA>? NH;KUoZKSzVyPUmuO|MhyrFiMj6xNkDPxE1? NHLiUm8zPDB4NUW2PS=>
U373  MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGDDRYQyOC1{MECg{txO MkPCPVYhcA>? MXXJR|UxRTFyLkGzJOKyKDFwMEKg{txO MXOyOFA3PTV4OR?=
HT-29  MXXGeY5kfGmxbjDBd5NigQ>? MojsOVAxKM7:TR?= NIT3TFYzPC92ODDo M{\rb4VvcGGwY3XzJJRp\SCuZY\lcJMhd2ZizsOtTFJCYMLi M2\JbFI1ODN6ME[4
PC-3  MnrIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWqyT3NvOC1{NTFOwG0> NFTPOlY1QCCq MoThbY5pcWKrdIOgZ4VtdCCpcn;3eIghf2irY3igZ4FvKGKnIIDveIVvfGmjdHXkJIJ6KGy7Y3;w[Y5m NHSz[XIzOzd2NkmzOC=>
PC-3  MYHBdI9xfG:|aYOgRZN{[Xl? M1\Bb|I2KM7:TR?= MV20PEBp MWnpcoR2[2W|IHHwc5B1d3OrczD3bIlkcCClYX6gZoUheG:2ZX70bYF1\WRiYomgcJlkd3CnbnW= MmHINlM4PDZ7M{S=
T98G NVXXWnNmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWnsdGFIPTBvNECwJO69VQ>? MVqxOFQhcA>? MVrpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? MXmyN|cyPTR7OR?=
U87-MG MoTMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1fpXFExOCEEtV2= NV:0NWZ1PzJiaB?= MVPpcohq[mm2czDj[YxtKGe{b4f0bEB4cGmlaDDjZY4h[mViZX7oZY5k\WRiYomgS3RD MYqyN|Y6Pjd6OB?=
U251-MG NXSxRZlHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo\HNVAxKML3TR?= NHrIV5o4OiCq MmPrbY5pcWKrdIOgZ4VtdCCpcn;3eIghf2irY3igZ4FvKGKnIHXubIFv[2WmIHL5JGdVSg>? MnnKNlM3QTZ5OEi=
LNT-229 M{nUdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYTtfphuOy1zMECg{txO MkXrNlQhcA>? M{DJOolvcGmkaYTzJINtd26xZ3XubYMhe3W{dnn2ZYwhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NFThemwzOzZ4N{[zNi=>
T98G NUDSUVlzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmnYNVAuPzByIN88US=> NYrrZoI1OjRiaB?= MkH3bY5pcWKrdIOgZ4xwdm:pZX7pZ{B{fXK4aY\hcEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> M{f5c|I{PjZ5NkOy
U87  MXvGeY5kfGmxbjDBd5NigQ>? M3jHUVExOCEEtV2= NVGyeVREOyCq MoLr[YxmfmG2ZYOgeIhmKGyndnXsd{Bw\iCyQ3jrNUBidmRicFPob|I> MViyN|Y3PzR4OR?=
HCT116 MmfpSpVv[3Srb36gRZN{[Xl? NHjxS|MyODBiwsXN Mn3kN{Bp Mnm1bY5lfWOnczD0bIUhS2itMTDQbI9{eGixconsZZRqd25? MVeyN|Y3PzR4OR?=
HCT3-6 MlzBSpVv[3Srb36gRZN{[Xl? NGHSNXEyODBiwsXN NIDiXG4{KGh? M1\q[Ilv\HWlZYOgeIhmKEOqa{GgVIhwe3Cqb4L5cIF1cW:w MnXhNlM3Pjd2Nkm=
U-87  NV7xNpdGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWexS4RrOC12MDFOwG0> NHfNNmsyOiCm NXzHdYREcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NFjDcZEzOzZ2NUeyPS=>
U-87  NXf3W2JDSXCxcITvd4l{KEG|c3H5 M{nTb|AuPDBizszN M4rCZVMwPiCm MXjpcoR2[2W|IHHwc5B1d3OrczDpckBjd3SqIHTvd4UuKGGwZDD0bY1mNWSncHXu[IVvfCCvYX7u[ZI> MW[yN|Y1PTd{OR?=
U-87  MULGeY5kfGmxbjDBd5NigQ>? MViwMVQxKM7:TR?= MlL1N{83KGR? Ml7ObY5lfWOnczDheZRweGijZ4mgbY4h[m:2aDDkc5NmNSCjbnSgeIlu\S2mZYDlcoRmdnRibXHucoVz M164ZlI{PjR3N{K5
GB-SCC010 M3zzeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYO5XHhIPCCm NIO2SINKSzVyPUKyOkDPxE1? MX[yN|YyOjd3NR?=
GB-SCC026 M1fqcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnW4OEBl NXLodJJEUUN3ME21N{4yKM7:TR?= MYKyN|YyOjd3NR?=
GB-SCC028 NGfRNZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo\5OEBl NIS0OmtKSzVyPUG2O{DPxE1? MnjBNlM3OTJ5NUW=
U87 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoHZOEBl NGfmcYdKSzVyPUS1MlIh|ryP M2X4SlI{PjF{N{W1
U87 stem cell NH7JeY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlToOEBl NF\HPW9KSzVyPU[2Mlch|ryP MYiyN|YyOjd3NR?=

... Click to View More Cell Line Experimental Data

In vivo After a daily i.p. dose of 40 mg/kg for 5 consecutive days (days 1-5 after tumor transplant), methazolastone increases life-span by 86% in L-1210 and 22% in L-1210/BCNU. In L-1210/BCNU no effect is seen after 100 μM or 200 μM treatment; only 400 μM methazolastone produced an accumulation of cells in premitotic phase but much less than in L-1210. In L-1210/BCNU the maximum accumulation of cells in SL-G2-M is, after 48 hours-72 hours, approximately 30% as compared to 23% in untreated cells. Cells accumulates in SL-G2-M occurred too when L- 1210 leukemia-bearing mice are treated i.v. with methazola stone (40 mg/kg). No such effect is seen on L-1210/BCNU cells from mice given the same drug dose. [1]

Protocol

Cell Research:

[1]

+ Expand
  • Cell lines: L-1210 and L-1210/BCNU cells
  • Concentrations: 0 μM -100 μM
  • Incubation Time: l hours
  • Method:

    L-1210 and L-1210/BCNU cells are seeded at 0.2 × 104 cells/mL and incubated for 24 hours. The cultures are treated with Methazolastone for l hours at 37oC, then washed twice in PBS by centrifugation and resuspended in fresh medium. Controls and treated samples are diluted in fresh medium 1:4 at 48 hours and 1:2 at 96 hours. Using these dilutions cell concentrations throughout the experiments are between 3 × 105 and 8 × 105/mL. Control growth is logarithmic in this range.


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: DBA/2 mice with L-1210 and L-1210/BCNU cells
  • Formulation: 95% ethanol
  • Dosages: 40 mg/kg
  • Administration: Administered via i.v.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 38 mg/mL (195.72 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+30% PEG 300+ddH2O
For best results, use promptly after mixing.
2mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 194.15
Formula

C6H6N6O2

CAS No. 85622-93-1
Storage powder
in solvent
Synonyms CCRG81045, NSC 362856

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

DNA/RNA Synthesis Signaling Pathway Map

Related DNA/RNA Synthesis Products0

Tags: buy Temozolomide | Temozolomide ic50 | Temozolomide price | Temozolomide cost | Temozolomide solubility dmso | Temozolomide purchase | Temozolomide manufacturer | Temozolomide research buy | Temozolomide order | Temozolomide mouse | Temozolomide chemical structure | Temozolomide mw | Temozolomide molecular weight | Temozolomide datasheet | Temozolomide supplier | Temozolomide in vitro | Temozolomide cell line | Temozolomide concentration | Temozolomide nmr
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID